Back and forth we go.

Back and forth we go.

Oscar Wilde is famous for saying “Imitation is the sincerest form of flattery” which in essence is the perfect description for Abbott’s earnings call today. Back during ADA their archrival and nemesis Dexcom announced new products targeted at less intensively managed patients. A product which would also work well in the expanding market outside of diabetes. So, what does Abbott do? Yep, you guessed it they also announced they too have a 15-day sensor, and they too are going after people who use CGM for general health.

Just as diabetes drugs have become part of the weight loss . . .

This content is restricted to subscribers. Please subscribe.

Already have an account? Please login.